ÂÜÀòÂÒÂ×

Bill Bradford, MD, PhD, currently serves as a member of the Board of Directors at Endeavor BioMedicines and Teton Bioscience, among other organizations. With extensive experience in the biotechnology and life sciences sectors, Bill held various leadership positions, including Principal at Teton Bioscience since March 2015 and Senior Vice President of Clinical Development at InterMune from November 2001 to October 2014. Bill is also known for founding Cascadia Therapeutics, which was acquired by Antegrin Therapeutics in 2016, and Indalo Therapeutics, where Bill served as Chief Medical Officer and Board Director until August 2020. Education includes a Bachelor's Degree from Williams College, completed from 1980 to 1984.